Pregabalin Capsule
Product Images NDC 14445-127

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 14445-127). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Indoco Remedies Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100mg-label (100mg Label)

Pregabalin 100 mg capsules packaging label from Indoco Remedies Limited. The label shows the product name, strength, dosage form, quantity (90 capsules), and storage instructions. It includes a bar code and space for NDC, lot, and expiration details. The label also has directions for pharmacists to dispense the medication guide to patients.*

FDA Label Image

150mg-label (150mg Label)

Label for Pregabalin Capsules 150 mg by Indoco Remedies Limited. The label indicates 150 mg strength capsules with a package size of 90 capsules. It includes storage instructions, pharmacist dispensing guidance, and manufacturer details. The NDC number 14445-125-90 is shown along with a barcode and space for overprint information such as expiration date and lot number.*

FDA Label Image

200mg-label (200mg Label)

Pregabalin Capsules 200 mg oral dosage form in a 90-capsule package by Indoco Remedies Limited. The label includes drug strength, bar code, storage instructions (25°C, excursions permitted 15-30°C), and directions to dispense a medication guide to patients. It specifies prescription-only use and features a pharmaceutical code section.*

FDA Label Image

225mg-label (225mg Label)

Label for Pregabalin Capsules 225 mg manufactured by Indoco Remedies Limited. The label states the product contains 225 mg of pregabalin per capsule, with 90 capsules per container. It includes storage instructions, a barcode, and placeholders for GTIN, expiration date, lot number, and UID. The label notes the medication is prescription-only (Rx ONLY).*

FDA Label Image

Container-label (25 mg 173)

Pregabalin Capsules 25 mg oral dosage form label, packaged by Indoco Remedies Limited. The label indicates 90 capsules per container with instructions for storage at 25°C (77°F) with allowable excursions, and dispensing in child-resistant containers. The label includes a National Drug Code (NDC), barcode, and manufacturer address in Goa, India.*

FDA Label Image

300mg-label (300mg Label)

Label for Pregabalin Capsules 300 mg by Indoco Remedies Limited. The label includes dosage details, NDC number 14445-128-90, instructions for storage at 25°C with allowed excursions, and medication dispensing guidance. The package contains 90 capsules, with dimensions 120 mm by 50 mm visible.*

FDA Label Image

Container-label-50 (50 mg 174)

Pregabalin Capsules 50 mg oral dosage form label from Indoco Remedies Limited. The label indicates a 90-capsule supply with each capsule containing 50 mg of pregabalin. Storage instructions specify maintaining 25°C (77°F) with allowed excursions from 15 to 30°C (59 to 86°F). The label includes a UPC barcode and pharmacist dispensing instructions, emphasizing the enclosed Medication Guide for patients.*

FDA Label Image

75mg-label (75mg Label)

Label for Pregabalin Capsules 75 mg by Indoco Remedies Limited, showing a 90-capsule count. The label includes dosage strength of 75 mg pregabalin per capsule, NDC 14445-123-90, storage instructions, and manufacturer information from Verna, Goa, India. Also visible is a barcode and caution about child-resistant packaging.*

FDA Label Image

Fig 10 (Fig 10 Pregabalin)

This is a Kaplan-Meier survival curve chart comparing the estimated percentage of subjects without LTR (lack of therapeutic response or relevant event) over a 180-day period for Pregabalin versus placebo. The x-axis represents time in days, and the y-axis represents the estimated percentage of subjects without LTR.*

FDA Label Image

Fig-8 (Fig 8)

A bar graph depicting responder rates (%) for three groups: Placebo (22.6%), 2.5 mg/kg/day (29.1%), and 10 mg/kg/day (40.6%). The x-axis lists treatment groups with corresponding sample sizes: Placebo (93), 2.5 mg/kg/day (103), and 10 mg/kg/day (96). The y-axis represents responder rate percentages from 0 to 60%.*

FDA Label Image

Figure 2 (Figure2)

A line chart comparing the percent of patients improved versus percent improvement in pain from baseline for pregabalin 100 mg three times a day and placebo. The y-axis shows percent of patients improved, and the x-axis shows percent improvement in pain from baseline. The chart displays two lines, one for pregabalin and one for placebo, illustrating differences in patient improvement responses.*

FDA Label Image

Str (Pegabalin Str)

Chemical structure of pregabalin, showing its molecular formula with characteristic functional groups including an amino group (NH2) and a carboxylic acid (CO2H) attached to a branched carbon chain.*

FDA Label Image

Fig 1 (Preagabalin Fig1)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 200 mg three times a day, 100 mg three times a day, 25 mg three times a day, and placebo, showing trends of patient improvement for each dosage.*

FDA Label Image

Fig 11 (Preagabalin Fig10)

Kaplan-Meier curve graph showing the percent of subjects improved over time comparing pregabalin versus placebo. The x-axis represents percent improvement from baseline to Week 12 BOCF, and the y-axis shows the percent of subjects improved. Two curves are displayed: a solid line for pregabalin and a dashed line for placebo, illustrating higher improvement percentages for pregabalin across the study period.*

FDA Label Image

Fig 12 (Preagabalin Fig11)

A cumulative response curve chart showing percent of subjects improved on the Y axis and percent improved from baseline to week 16 on the X axis. The chart compares pregabalin to placebo, with pregabalin represented by a solid line consistently showing a higher percentage of subjects improved than the placebo represented by a dashed line.*

FDA Label Image

Fig3 (Preagabalin Fig3)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. It compares pregabalin at dosages of 75 mg, 150 mg, and 300 mg taken twice a day, along with a placebo group. The graph illustrates trends in patient improvement across varying levels of pain reduction.*

FDA Label Image

Fig4 (Preagabalin Fig4)

A line graph comparing the percent improvement in pain from baseline among three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph plots percent of patients improved against percent improvement in pain, showing trends across different thresholds of pain improvement.*

FDA Label Image

Fig 5 (Preagabalin Fig5)

A line graph showing the percent improvement in pain from baseline on the x-axis and the percent of patients improved on the y-axis for three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph compares the effectiveness of the two doses of pregabalin against placebo over a range of pain improvement percentages.*

FDA Label Image

Figure6 (Preagabalin Fig6)

A bar chart comparing responder rates in percentages for pregabalin doses versus placebo in two studies, Study E1 and Study E3. The x-axis shows different treatments including placebo and varying doses of pregabalin, while the y-axis represents the responder rate percentage, ranging from 0 to 60%. Sample size for each group is indicated below the x-axis categories.*

FDA Label Image

Fig 7 (Preagabalin Fig7)

A line graph illustrating dose-dependent seizure reduction as median percent change from baseline across four studies (E1 BD, E2 TID, E3 BID, E3 TID) for pregabalin. The x-axis shows dose in mg/day up to 600 mg, and the y-axis shows seizure reduction percentage up to 60%. Significant p-values are annotated for doses of approximately 75, 150, 300 mg/day and above.*

FDA Label Image

Fig 9 (Preagabalin Fig8)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline for pregabalin doses of 600 mg, 450 mg, 300 mg daily, and placebo. The graph shows four lines representing the different doses and placebo with percent improvement in pain on the x-axis and percent of patients improved on the y-axis.*

FDA Label Image

Eq (Pregabalin Eq)

A mathematical formula calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a correction factor for female patients. The formula is presented in a text snippet likely from prescribing or pharmacokinetic information related to pregabalin capsules by Indoco Remedies Limited.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.